Welcome to our dedicated page for Biolife Solutions SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioLife Solutions, Inc. (NASDAQ: BLFS) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on BioLife’s activities as a developer and supplier of cell processing tools and services and bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets.
Through periodic reports such as the Form 10-K annual report and Form 10-Q quarterly reports, investors can review disclosures on BioLife’s Cell Processing, Cold Chain, and Thawing product areas, its focus on biopreservation media and related tools, and the financial impact of divestitures and strategic transactions. These filings also describe the company’s use of GAAP and non-GAAP metrics, its presentation of discontinued operations related to divested subsidiaries, and other elements of its financial reporting framework.
Current reports on Form 8-K highlight specific material events, including quarterly earnings announcements, investor presentations, and the sale of its evo cold chain logistics subsidiary. Proxy materials such as the definitive proxy statement (DEF 14A) provide insight into corporate governance, board composition, executive compensation proposals, and matters submitted to stockholder votes at the annual meeting.
On Stock Titan, each new BioLife filing is captured from EDGAR and paired with AI-powered summaries that explain the key points in clear language. Users can quickly scan annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K) to understand changes in BioLife’s cell processing business, portfolio evolution, and governance decisions. The filings page also surfaces information relevant to topics such as equity awards and compensation policies discussed in proxy statements, helping investors interpret the regulatory record behind the BLFS stock.
BioLife Solutions, Inc. (BLFS) Rule 144 notice reports a proposed sale of 500,000 common shares through BMO Capital Markets on 08/15/2025 with an aggregate market value of $12,660,000. The filing states total shares outstanding of 47,905,265. The securities to be sold were acquired in three cash purchases: 250,000 on 07/02/2020, 100,000 on 12/16/2020, and 150,000 on 04/30/2024. The filer discloses prior sales by Casdin Partners Master Fund, L.P.: 1,000,000 shares on 06/10/2025 and 500,000 shares on 08/11/2025 with stated gross proceeds.
T. Rowe Price Investment Management, Inc. reports holding 4,246,706 shares of BioLife Solutions common stock, representing 8.9% of the class. The filing is a Schedule 13G filed by an investment adviser (classification IA) and indicates sole voting and sole dispositive power over those shares. The filer certifies the securities were acquired and are held in the ordinary course of business and states they were not acquired to change or influence control of the issuer. The filing also includes a declaration denying beneficial ownership in a closing certification.
Casdin-related reporting persons disclosed beneficial ownership of 7,207,165 shares of BioLife Solutions, Inc. That stake represents 15.0% of the company based on 47,905,265 shares outstanding as of July 31, 2025. The filing names Casdin Capital, LLC; Casdin Partners Master Fund, L.P.; Casdin Partners GP, LLC; and Eli Casdin as the reporting persons.
The filing states the Fund used its working capital to purchase the shares and did not use borrowed funds except for ordinary working capital borrowing. The Reporting Persons say they currently have no plans to change board composition, management, capitalization or dividend policy but reserve the right to propose or effect such changes and to engage with management and other shareholders about maximizing shareholder value.
Casdin Partners Master Fund, L.P. reported an insider sale of BioLife Solutions, Inc. (BLFS) common stock on 08/11/2025. The filing shows a reported sale of 500,000 shares at a price of $22.60 per share. The transaction is recorded with transaction code S indicating a disposition.
The filing identifies related reporting entities—Casdin Capital, LLC; Casdin Partners GP, LLC; and Eli Casdin—and states the securities are owned directly by the Master Fund and may be indirectly beneficially owned by those entities. After the reported transaction the reporting persons are shown as beneficially owning 7,207,165 shares indirectly.
BioLife Solutions (BLFS) Form 144 discloses a proposed sale of 500,000 shares of common stock through BMO Capital Markets on NASDAQ with an aggregate market value of $11,185,000. The filing reports 47,905,265 shares outstanding and an approximate sale date of 08/11/2025.
The shares were acquired on 12/16/2020 by purchase from a shareholder and paid in cash. The filing also lists a recent sale by Casdin Partners Master Fund, L.P. of 1,000,000 shares on 06/10/2025 for $23,800,000. The seller certifies they are unaware of any undisclosed material adverse information.
BioLife Solutions Inc. (BLFS) – Form 4 filing: Chief Human Resources Officer Sarah Aebersold sold 198 shares of common stock on 7 July 2025 at $22.27 per share under a pre-established Rule 10b5-1 trading plan. The sale was executed to cover tax-withholding obligations associated with previously vested restricted stock. After the transaction, the officer still owns 78,523 shares, which continue to be held directly. No derivative security activity was reported.
The transaction represents <0.3% of the insider’s total direct holdings and does not indicate a change in her overall investment thesis or role at the company. As such, the filing is considered routine and of low financial materiality for most investors.